

Leading Clients Across The Globe



By the Numbers

1,000+
Life sciences and healthcare industry clients and investors

The 10 largest
Global pharma/biotech companies

8 of the top 10
Largest medical technology / medical device companies

400+
Life sciences and healthcare deals in the last three years

300+
Life sciences and healthcare lawyers globally

50+
Years of experience in the industry

For general inquiries, please contact
RopesGrayatJefferies2025@ropesgray.com



NOVEMBER 2025

Global Life Sciences Capabilities



About Us

The most respected companies in the world choose Ropes & Gray to help build their businesses, capitalize on their greatest opportunities and get the best outcomes. We serve a marquee client base in the industries that shape the global economy—life sciences, healthcare, private equity, asset management, infrastructure, technology, business restructuring and more. We offer unrivaled experience in every sector in which our clients invest, as well as comprehensive regulatory, enforcement and litigation strategies. Clients trust us as their closest business advisors, and as tough negotiators and advocates who get results. Through developing creative solutions in domestic and cross-border matters, we help clients make sense of the complex legal landscape in today's world.

With over 300 life sciences and health care attorneys, we provide extensive expertise at the intersection of biopharma, regulatory frameworks, and capital markets, making us a trusted partner in navigating the industry's complexities globally. Our historical strengths include transactions, regulatory (including the leading legal voices in European and Asian regulatory and enforcement), data privacy, intellectual property, and government enforcement, among others. Through our collaborative approach, we are uniquely positioned to provide cutting-edge solutions to help clients meet their business goals.

SPECIALIZATIONS





- Venture, growth & crossover investments
- Licensing and collaborations
- Mergers, acquisitions and divestitures
- Private equity transactions
- Regulatory and compliance counseling
- Patent strategy and diligence
- Antitrust and competition
- Drug pricing strategy
- Transactional tax
- Capital markets transactions

“On any issue that arises, they have an expert who can help with clear, concise advice.”





— Client, *Chambers Global*

HIGHLIGHTS OF OUR GLOBAL EXPERIENCE





VENTURE INVESTMENT

 <p>Advised Bain Capital in its \$600 million Series B financing of Kailera, a clinical-stage biopharmaceutical company focused on advancing therapies for obesity</p>	 <p>Advised TPG in its Series B financing of Adcendo, a Denmark-based biotech company developing first-in-class ADCs</p>	 <p>Advised Northpond Ventures in the Series Seed financing of UK-based Mestag, a breakthrough inflammatory disease and immuno-oncology company</p>	 <p>Advised RTW Investments in its \$140 million Series A financing of UK-based Ottimo Pharma, a biotech focused on treating solid tumors</p>
--	---	--	--





CORPORATE VENTURE INVESTMENT

 <p>Advised Sanofi and EQT in the \$135 million Series B financing for SpliceBio, a Spain-based genetic medicines company</p>	 <p>Advised Pfizer Ventures in the £25.2 million Series D financing for UK-based Mission Therapeutics, a biotech specializing in deubiquitylating enzymes</p>	 <p>Advised Sanofi in the \$140 million Series A financing of UK-based Draig Therapeutics, a biotech developing treatments for neuropsychiatric disorders</p>	 <p>Advised Pfizer Ventures in the \$31 million Series Seed financing in UK-based TRIMTECH Therapeutics, a biotech addressing neurodegenerative diseases</p>
---	--	--	---


EMERGING COMPANY

 <p>Advised UK-based Basecamp Research in its \$60 million Series B financing</p>	 <p>Advised UK-based Fraiya in its spin-out and Series Seed financing</p>	 <p>Advised Zenas BioPharma in its \$200 million Series C financing and in its subsequent \$225 million initial public offering</p>	 <p>Advised Dash Bio in its formation, its \$6.5 million Series Seed financing and its \$11 million Series Seed-2 financing</p>
---	--	--	--

LICENSING AND COLLABORATIONS

 <p>Advised Novo Nordisk in expanding its collaboration with Valo in a deal worth up to \$4.6 billion to develop treatments for obesity, type 2 diabetes, and cardiovascular disease</p>	 <p>Advised Italy-based Chiesi in its global strategic collaboration with Gossamer to develop and commercialize Gossamer's seralutinib</p>	 <p>Advised Netherlands-based Prilenia in a licensing agreement with Ferrer International for Prilenia's pre-commercial sigma-1 receptor agonist Pridopidine</p>	 <p>Advised UK-based Apollo in its licensing agreement with Sunshine Lake Pharma to develop and commercialize a clinical stage FGF21/GLP-1 dual receptor agonist</p>
---	---	---	---





MERGERS & ACQUISITIONS

 <p>Advised Novo Nordisk in the acquisition of Akero Therapeutics, a clinical stage company developing treatments for patients with metabolic diseases for up to \$5.2 billion</p>	 <p>Advised Sanofi in its option to acquire Dren Bio's deep B-cell depleter program, DR-0201, in a deal worth up to \$1.9 billion</p>	 <p>Advised Eli Lilly in its acquisition of Scorpion Therapeutics and its PI3Ka cancer program in a deal valued at up to \$2.5 billion</p>	 <p>Advised AbbVie in the acquisition of Capstan Therapeutics, a cell therapy developer, for up to \$2.1 billion</p>
---	--	---	---

ANTITRUST AND COMPETITION

 <p>Advised uniQure on its exclusive worldwide license of Hemophilia B gene therapy to CSL Behring for \$450 million upfront and up to \$1.6 billion in milestones. The transaction cleared without challenge despite a Second Request from FTC</p>	 <p>Advised AbbVie in its \$21 billion acquisition of Pharmacyclics, which obtained FTC approval without Second Request</p>	 <p>Advised Sarepta as antitrust counsel in a global licensing and collaboration agreement with Arrowhead worth up to \$11.35 billion</p>	 <p>Advised Provention Bio, amidst heightened oversight and scrutiny of global merger control by the FTC, on its sale to Sanofi in a deal worth \$2.9 billion</p>
---	--	--	--

PRIVATE EQUITY TRANSACTIONS

 <p>Advised Partners Group in its acquisition of Pharmathen, a Greece-based pharma and, subsequently, Pharmathen on its acquisition of CBL Patras</p>	 <p>Advised GHO on its acquisition of Envision Pharma and the subsequent add-on acquisitions by Envision Pharma of Two Labs and OKRA.ai</p>	 <p>Advised Avista Capital Partners on its acquisition of Terrats Medical, a Spain-based manufacturer of dental implants and prostheses, from Miura Partners</p>	 <p>Advised Advent International and Warburg Pincus in their investment in Baxter International's BioPharma Solutions (BPS) business</p>
---	--	---	---

Award-Winning, Reliable Service

Corporate Firm of the Year & United Kingdom Firm of the Year

LMG Life Sciences Awards EMEA 2024

Licensing and Collaboration Firm of the Year

Three-time winner

LMG Life Sciences Awards

Firm of the Year IP Transactions

Managing IP Americas 2023 & 2025

Dealmakers of the Year

The American Lawyer 2024

Top-Tier Life Sciences Regulatory / Compliance practice

Chambers USA 2025

Firm of the Year / Venture Capital

LMG Life Sciences Awards EMEA 2025

UK Life Sciences Firm of the Year

LMG Life Sciences EMEA Awards 2024

Leading Firm

Leading Firm Multi-Jurisdictional: Life Sciences Chambers Global 2024

Corporate Practice of the Year

Pharma and Health Care

The American Lawyer Industry Awards 2022 & 2024

16 OFFICES WORLDWIDE

